NCT00841217

Regulation of Lipoprotein Transport in Metabolic Syndrome

Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: The University of Western Australia · Academic / Other
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.

Detailed description

The metabolic syndrome (MetS) portends diabetes and cardiovascular disease (CVD). Dyslipoproteinaemia, reflected by elevated plasma triglyceride and reduced high-density lipoprotein (HDL) concentrations, is a cardinal feature of MetS that independently predicts CVD and is accordingly a therapeutic target for risk reduction. GW5015156 is a new PPAR-delta agonist that could be used to treat dyslipidemia in insulin resistance and obesity. However, the precise mechanisms of action of this agent on lipoprotein kinetics in MetS subjects have not yet fully been investigated. We therefore carried out a study to study the effect of GW5015156 on lipoprotein transport in subject with metabolic syndrome.

Conditions

• Obesity
• Lipid Disorders
• Cardiovascular Disease

Interventions

Type	Name	Description
DRUG	GW501516	2.5mg/day
DRUG	placebo pill

Timeline

• Start date: 2003-04-01
• Primary completion: 2005-08-01
• Completion: 2008-12-01
• First posted: 2009-02-11
• Last updated: 2009-02-11

Locations

1 site across 1 country: Australia